摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,7-dimethyl-1,2,3,7-tetrahydro-imidazo[1,2-a]pyridine-6,8-dicarboxylic acid diethyl ester | 50620-14-9

中文名称
——
中文别名
——
英文名称
5,7-dimethyl-1,2,3,7-tetrahydro-imidazo[1,2-a]pyridine-6,8-dicarboxylic acid diethyl ester
英文别名
5,7-Dimethyl-1,2,3,7-tetrahydroimidazolo[1,2-a]pyridine-6,8-dicarboxylic acid diethyl ester;diethyl 5,7-dimethyl-1,2,3,7-tetrahydroimidazo[1,2-a]pyridine-6,8-dicarboxylate
5,7-dimethyl-1,2,3,7-tetrahydro-imidazo[1,2-<i>a</i>]pyridine-6,8-dicarboxylic acid diethyl ester化学式
CAS
50620-14-9
化学式
C15H22N2O4
mdl
——
分子量
294.351
InChiKey
CVZPNINXMFGHOE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    138 °C
  • 沸点:
    418.0±45.0 °C(Predicted)
  • 密度:
    1.19±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    21
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    67.9
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • Tetrahydroimidazolo[1,2-a]pyridine derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US03935220A1
    公开(公告)日:1976-01-27
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,6-位可选择性地被低碳基取代,4-位被低碳基、苯基、取代苯基或杂环基所取代,并通过1-和2-位融合到五、六或七元环烷基环上,其中一个亚甲基可以被、氧、亚基或烷基亚基所取代,是抗高血压药和冠状血管扩张剂。这些化合物,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个代表性实施例,是通过酰乙酰酸酯和环状烯酮羰基衍生物的缩合制备的。
  • Pentahydroqunolizine derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US03948923A1
    公开(公告)日:1976-04-06
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are anti-hypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropridine-3,5-dicar boxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,6-位可选择性地被低烷基取代,4-位被低烷基、苯基、取代苯基或杂环基取代,通过1-和2-位与五、六或七元环环烷基融合,其中一个亚甲基可以被、氧、亚胺或烷基亚胺取代,是降压剂和冠状血管扩张剂。这些化合物通过酰乙酸乙酯和环状烯酮羰基衍生物的缩合反应制备而成,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸乙酯是一种代表性的实施例。
  • Tetrahydroindolizine derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US03951994A1
    公开(公告)日:1976-04-20
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,可在6-位被低烷基取代,4-位被低烷基、苯基、取代苯基或杂环基取代,并通过1-和2-位融合到五、六或七元环环烷基环上,其中一个亚甲基可以被、氧、亚基或烷基亚基替换,是降压剂和冠状血管扩张剂。这些化合物的代表性实施例是6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯,通过酰乙酰乙酸酯和环状烯酰亚胺羰基衍生物的缩合制备。
  • Bicyclic derivatives of 1,4-dihydropyridine as antihypertensive agents
    申请人:Bayer Aktiengesellschaft
    公开号:US04004015A1
    公开(公告)日:1977-01-18
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,可在6-位被低碳基取代,在4-位被低碳基、苯基、取代苯基或杂环基取代,并通过1-和2-位融合到五、六或七元环烷基环上,其中一个亚甲基可以被、氧、亚基或烷基亚基取代,是抗高血压药物和冠状血管扩张剂。这些化合物通过酰乙酰乙酸酯和环状烯酮羰基衍生物的缩合制备,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸乙酯是一个典型的实施例。
  • Compositions and methods employing tetrahydroindolizine derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US04024261A1
    公开(公告)日:1977-05-17
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are anti-hypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    在3-和5-位置带有羰基功能的1,4-二氢吡啶,可以在6-位置被低级烷基取代,4-位置被低级烷基、苯基、取代苯基或杂环基取代,并通过1-和2-位置与五、六或七元环烷基环融合,其中一种亚甲基基团可以被、氧、亚胺或烷基亚胺取代,是抗高血压药物和冠状血管扩张剂。这些化合物,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个具有代表性的实施例,可以通过酰乙酰乙酸酯和环状烯胺羰基衍生物的缩合制备。
查看更多

同类化合物

阿法拉定A,TFA 钠咪唑并[1,2-a]吡啶-2-羧酸酯水合物(1:1:1) 钠(E)-2-氰基-3-[2,8-二(丙-2-基氧基)咪唑并[3,2-a]吡啶-3-基]丙-2-烯酸酯 诺白拉斯啶 苯酚,4-(5,6,7,8-四氢咪唑并[1,2-a]吡啶-8-基)- 米诺膦酸 米诺磷酸一水合物 硫酸利美戈潘 盐酸法屈唑半水合物 盐酸依格列汀 甲基咪唑并[1,5-A]吡啶-1-甲酸叔丁酯 甲基3-氨基咪唑并[1,2-a]吡啶-5-羧酸酯 甲基-(7-甲基咪唑并[1,2-A〕吡啶-2-基甲基)-胺 甲基-(5-甲基-咪唑并[1,2-A]吡啶-2-甲基)-胺 甲基 2-甲基咪唑并[1,2-a]吡啶-3-羧酸 环戊烷羧酸2-氨基-4-亚甲基-,(1R,2S)-(9CI) 环巴胺抑制剂1 泰妥拉唑 法倔唑盐酸盐 法倔唑 沃利替尼(对映异构体) 沃利替尼 氨基膦酸杂质14 戊酰胺,N-(2-丁基-1H-咪唑并[4,5-b]吡啶-6-基)- 巴马鲁唑 奥克塞米索 地扎胍宁甲磺酸盐 地扎胍宁 土大黄甙 咪唑磺隆 咪唑并吡啶-6-甲胺盐酸盐 咪唑并吡啶-2-酮盐酸盐 咪唑并吡啶-2-酮 咪唑并二甲基吡啶 咪唑并[2,1-a]异喹啉-2(3H)-酮 咪唑并[1,5-a]喹唑啉,6-氯-3-(3-环丙基-1,2,4-噁二唑-5-基)-5-(4-吗啉基)- 咪唑并[1,5-a]吡啶-8-胺 咪唑并[1,5-a]吡啶-8-羧酸乙酯 咪唑并[1,5-a]吡啶-8-甲醛 咪唑并[1,5-a]吡啶-7-羧酸甲酯 咪唑并[1,5-a]吡啶-7-羧酸乙酯 咪唑并[1,5-a]吡啶-6-羧酸甲酯 咪唑并[1,5-a]吡啶-6-羧酸乙酯 咪唑并[1,5-a]吡啶-5-胺 咪唑并[1,5-a]吡啶-5-羧酸甲酯 咪唑并[1,5-a]吡啶-5-羧酸乙酯 咪唑并[1,5-a]吡啶-5-甲醛 咪唑并[1,5-a]吡啶-3-羧酸乙酯 咪唑并[1,5-a]吡啶-3-磺酰胺 咪唑并[1,5-a]吡啶-3-甲醛